InvestSMART

Emyria Limited (ASX:EMD)

ALERT: Price-sensitive ASX Announcement for EMD
Current share price for EMD : $0.038 -0.02 (-34.48%)+
Announcement
Release
2 Feb 2026 9:24AM
Price at Release
$0.058
Full Release
download
Summary
Emyria Limited's PTSD program has shown lasting recovery results, with approximately two-thirds of patients achieving remission 12+ months post-treatment. As of December 31, 2025, the program has demonstrated strong clinical outcomes, reducing PTSD symptoms to below diagnostic thresholds. The program has screened over 100 patients, with many already receiving treatment or waiting to commence, indicating high demand. The company is pioneering treatments for severe PTSD, showing significant improvements and durable clinical benefits which are attractive to major payers seeking cost-effective models. Emyria's ongoing development includes screening for depression treatment and refining treatment protocols to enhance patient outcomes.
Key Points
  • Two-thirds of patients achieve remission one year after treatment.
  • Significant clinical improvement seen in 76% of patients.
  • Strong demand with over 100 patients screened and seeking treatment.
  • Ongoing development of a sustainable reimbursement model.
  • Expansion into broader mental health treatment programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.